Charles Swindell has over 30 years of experience in biopharmaceutical R&D, product development, and senior management in entrepreneurial life science companies.
He has been head of R&D at two companies, one in which he led the team during advancement of an oncology product into Phase III clinical development and was part of the senior management group that sold the business to a major Japanese pharma company, and another in which he was part of a turnaround effort that re-focused the company on biologic product development, played the lead role in the acquisition of a glyco-engineering technology platform from a Fortune 100 company and launched an endocrinology product development program.
Between these two positions Charles was part of a small senior team that optioned a late-stage oral hyperlipidemia product from a major university, took it through an end-of-Phase II meeting with the FDA, and then sold the rights to a venture-financed start-up company. He spent his earlier career in academia where he ran an internationally recognized NIH-funded research program, invented and licensed a manufacturing process operated by a major generic pharma company, and co-invented the above late-stage oncology product. Dr. Swindell received his PhD from Rice University and was a Swiss National Science Foundation Postdoctoral Fellow at the ETH-Zürich, Zürich, Switzerland.